United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read Pharma Industry News Indivior (Nasdaq: INDV) study supports 300 mg SUBLOCADE dose for fentanyl-heavy opioid use cases Indivior’s new trial results highlight how higher-dose SUBLOCADE may better support fentanyl users in OUD treatment. See what this means for the industry. bySrinathDecember 18, 2025